ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

17,614Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 463

$2.68M Total Retail Price of All Prescriptions

Rank: 1 out of 463

792 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
99% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 15,752 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

74% of this provider’s prescriptions were for brand-name drugs, compared to an average of 49%.

Prescription Price

$152 was the average price of a prescription from this provider, compared to $131 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SYNTHROID 1,312 1,206 1 2
JANUMET 947 885 10 2 17
ZETIA 818 741 10 3 33
ATELVIA 796 723 4 63
METFORMIN HCL 770 621 5 3
JANUVIA 699 622 6 6
CRESTOR 677 614 7 13
LOVAZA 631 569 8 39
PRANDIN 504 464 10 9 32
GLIMEPIRIDE 433 411 10 8
ACTONEL 408 401 11 55
VYTORIN 339 305 10 12 83
BYETTA 333 288 10 13 40
WELCHOL 316 277 10 14 78
LANTUS SOLOSTAR 299 275 15 4
TRADJENTA 277 267 10 16 91
LIPITOR 273 243 17 60
PEN NEEDLE 258 234 18 5
ALCOHOL SWABS 248 218 19 57
METFORMIN HCL ER 244 226 20 9
ATORVASTATIN CALCIUM 239 213 21 10
VICTOZA 3-PAK 227 191 22 30
SIMVASTATIN 202 190 23 7
TRILIPIX 198 165 24 123
METHIMAZOLE 193 180 25 21
FUROSEMIDE 193 184 25 25
ACTOS 189 182 27 24
SINGLE USE SWAB 186 151 28 58
BONIVA 181 171 29 135
HUMALOG MIX 75-25 174 137 30 49
GLYBURIDE-METFORMIN HCL 170 140 R 31 38
BYDUREON 140 97 32 117
ONGLYZA 136 120 33 50
PROLIA 136 135 33 139
UNIFINE PENTIPS 121 98 35 54
BENICAR HCT 112 102 36 124
DIOVAN HCT 112 98 36 59
PLAVIX 111 89 38 61
DIOVAN 108 93 39 42
METOPROLOL SUCCINATE 107 97 40 28
NOVOLOG FLEXPEN 107 107 40 11
ACTOPLUS MET 104 85 42 93
LEVEMIR FLEXPEN 103 76 43 19
LANTUS 90 62 44 16
ALENDRONATE SODIUM 80 65 45 22
BENICAR 80 71 45 145
RAMIPRIL 80 69 45 45
AMMONIUM LACTATE 80 68 45 87
IBANDRONATE SODIUM 79 78 49 158
NEXIUM 77 72 50 37
EXFORGE 75 73 51 101
AMLODIPINE BESYLATE 71 67 52 12
ENALAPRIL MALEATE 64 53 53 35
PROPYLTHIOURACIL 58 58 54 199
HUMALOG 57 45 55 14
INSULIN SYRINGE 56 50 56 18
ALCOHOL PREP PADS 56 45 56 108
LOSARTAN POTASSIUM 55 41 58 20
LYRICA 53 43 59 131
CARVEDILOL 51 30 60 47
NOVOLOG MIX 70-30 FLEXPEN 51 39 60 34
LOSARTAN-HYDROCHLOROTHIAZIDE 51 50 60 51
PRANDIMET 50 50 10 63 173
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 7, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.